Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders
Pilot Study of Glycine Augmentation in Carriers of a Mutation in the Gene Encoding Glycine Decarboxylase
Sponsor: Mclean Hospital
Listed as NCT01720316, this PHASE2 trial focuses on Bipolar Disorder and Schizo-affective Disorder and remains completed. Sponsored by Mclean Hospital, it has been updated 10 times since 2012, reflecting substantial change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
May 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE2
Status: Enrolling By Invitation → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Enrolling By Invitation PHASE2
First recorded
Dec 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mclean Hospital
- National Institute of Mental Health (NIMH)
For direct contact, visit the study record on ClinicalTrials.gov .